Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.
ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarfò L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA. ten Hacken E, et al. Among authors: burger ja. Haematologica. 2017 Oct;102(10):e394-e396. doi: 10.3324/haematol.2017.169102. Epub 2017 Jul 27. Haematologica. 2017. PMID: 28751563 Free PMC article. No abstract available.
CXCR4 is a prognostic marker in acute myelogenous leukemia.
Spoo AC, Lübbert M, Wierda WG, Burger JA. Spoo AC, et al. Among authors: burger ja. Blood. 2007 Jan 15;109(2):786-91. doi: 10.1182/blood-2006-05-024844. Epub 2006 Aug 3. Blood. 2007. PMID: 16888090 Free article.
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Niedermeier M, et al. Among authors: burger ja. Blood. 2009 May 28;113(22):5549-57. doi: 10.1182/blood-2008-06-165068. Epub 2009 Mar 24. Blood. 2009. PMID: 19318683 Free PMC article.
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Jabbour E, et al. Among authors: burger ja. Blood. 2009 Sep 3;114(10):2037-43. doi: 10.1182/blood-2009-01-197715. Epub 2009 Jun 30. Blood. 2009. PMID: 19567878 Free PMC article.
375 results